MAGEA6 (MAGE family member A6) functions as an activator of ubiquitin ligase activity, specifically enhancing RING-type E3 ubiquitin-protein ligases and acting as a repressor of autophagy 1. The protein forms a cancer-specific ubiquitin ligase complex with TRIM28 that targets AMPKα1 for ubiquitination and degradation, leading to inhibition of autophagy and activation of mTOR signaling 1. MAGEA6 is normally expressed only in male germline cells but becomes aberrantly reactivated in various human cancers including gliomas, colorectal cancer, pancreatic cancer, and acute myeloid leukemia 2345. In cancer contexts, MAGEA6 promotes cell survival and tumor progression through multiple mechanisms: it stabilizes transcription factor YY1 by inhibiting its ubiquitination, leading to enhanced CXCL1 expression and Schwann cell recruitment in colorectal cancer perineural invasion 3. The protein's expression is regulated by DNA methylation, with hypomethylating agents increasing MAGEA6 levels 5. Clinically, MAGEA6 expression correlates with poor prognosis and represents a potential therapeutic target, as its knockdown restores AMPK function and sensitizes cancer cells to metabolic stress 25.